EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice

Kristen H Schuster, Annie J Zalon, Danielle M DiFranco, Alexandra F Putka, Nicholas R Stec, Sabrina I Jarrah, Arsal Naeem, Zaid Haque, Hanrui Zhang, Yuanfang Guan, Hayley S McLoughlin

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.02.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Kristen H Schuster und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Oligodendroglia, Machado-Joseph Disease, Oligonucleotides, Antisense, Disease Models, Animal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIGMS NIH HHS, National Ataxia Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited ataxia. Currently, no preventive or disease-modifying treatments exist for this progressive neurodegenerative disorder, although efforts using gene silencing approaches are under clinical trial investigation. The disease is caused by a CAG repeat expansion in the mutant gene, ATXN3, producing an enlarged polyglutamine tract in the mutant protein. Similar to other paradigmatic neurodegenerative diseases, studies evaluating the pathogenic mechanism focus primarily on neuronal implications. Consequently, therapeutic interventions often overlook non-neuronal contributions to disease. Our lab recently reported that oligodendrocytes display some of the earliest and most progressive dysfunction in SCA3 mice. Evidence of disease-associated oligodendrocyte signatures has also been reported in other neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. Here, we assess the effects of anti-ATXN3 antisense oligonucleotide (ASO) treatment on oligodendrocyte dysfunction in premanifest and symptomatic SCA3 mice. We report a severe, but modifiable, deficit in oligodendrocyte maturation caused by the toxic gain-of-function of mutant ATXN3 early in SCA3 disease that is transcriptionally, biochemically, and functionally rescued with anti-ATXN3 ASO. Our results highlight the promising use of an ASO therapy across neurodegenerative diseases that requires glial targeting in addition to affected neuronal populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliaMachado-Joseph DiseaseOligonucleotides, AntisenseDisease Models, AnimalAtaxin-3AnimalsMiceHumansRepressor ProteinsMice, Transgenic

Stichwörter der Autor:innen

Machado-Joseph diseaseantisense oligonucleotideataxiamyelinationoligodendrocytepolyglutaminespinocerebellar ataxia type 3

Substanzen

Oligonucleotides, AntisenseAtaxin-3Atxn3 protein, mouseRepressor Proteins

Autor:innen und Institutionen

  • Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: hayleymc@med.umich.edu.

Förderung

  • NINDS NIH HHS
  • NIGMS NIH HHS
  • National Ataxia Foundation
  • Ionis Pharmaceuticals
  • NIH

Zitieren

APA

Schuster, K. H., Zalon, A. J., DiFranco, D. M., Putka, A. F., Stec, N. R., Jarrah, S. I., Naeem, A., Haque, Z., Zhang, H., Guan, Y., & McLoughlin, H. S. (2024). ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.02.033

Vancouver

Schuster KH, Zalon AJ, DiFranco DM, Putka AF, Stec NR, Jarrah SI, et al. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.02.033

BibTeX
@article{Schuster2024,
  author = {Schuster, Kristen H and Zalon, Annie J and DiFranco, Danielle M and Putka, Alexandra F and Stec, Nicholas R and Jarrah, Sabrina I and Naeem, Arsal and Haque, Zaid and Zhang, Hanrui and Guan, Yuanfang and McLoughlin, Hayley S},
  title = {ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.02.033}
}
Kostenlos starten →